Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML

Publication
Blood Advances, (3), 9, pp. 1379-1393, https://doi.org/10.1182/bloodadvances.2018028514
comments powered by Disqus

Related